Priya Singhal
Corporate Officer/Principal presso BIOGEN INC.
Patrimonio netto: 1 M $ in data 31/05/2024
Posizioni attive di Priya Singhal
| Società | Posizione | Inizio | Fine |
|---|---|---|---|
| BIOGEN INC. | Corporate Officer/Principal | 02/10/2023 | - |
| Direttore Tecnico/Scientifico/R&S | 31/12/2021 | 02/10/2023 |
Storia della carriera di Priya Singhal
Precedenti posizioni note di Priya Singhal
| Società | Posizione | Inizio | Fine |
|---|---|---|---|
| VERTEX PHARMACEUTICALS INCORPORATED | Direttore Tecnico/Scientifico/R&S | 01/01/2008 | 01/01/2012 |
| LARIMAR THERAPEUTICS, INC. | Direttore Tecnico/Scientifico/R&S | 04/03/2019 | - |
Formazione di Priya Singhal
| Harvard T.H. Chan School of Public Health | Graduate Degree |
| University of Mumbai | Doctorate Degree |
Statistiche
Distribuzione geografica
| Stati Uniti | 5 |
| India | 2 |
Posizioni
| Chief Tech/Sci/R&D Officer | 3 |
| Graduate Degree | 1 |
| Doctorate Degree | 1 |
Settori
| Health Technology | 4 |
| Consumer Services | 3 |
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Società collegate
| Società quotate in Borsa | 2 |
|---|---|
| BIOGEN INC. | Health Technology |
| VERTEX PHARMACEUTICALS INCORPORATED | Health Technology |
| Aziende private | 1 |
|---|---|
Zafgen, Inc.
 Zafgen, Inc. BiotechnologyHealth Technology Zafgen, Inc. is a biopharmaceutical company, which engages in the development of novel therapies for patients affected by complex metabolic diseases. It focuses on the study of MetAP2 inhibitors in both common and rare metabolic disorders. The firm also advancing programs for type 2 diabetes, Prader-Willi syndrome, and liver diseases. The company was founded on November 22, 2005 and is headquartered in Boston, MA. | Health Technology |
- Borsa valori
- Insiders
- Priya Singhal
- Esperienza
